KOMZIFTI (ziftomenib) Added to National Comprehensive Cancer Network (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for R/R NPM1-mutated…
ArriTech Announces Its Next-Generation QGen Online Platform for No-Code, AI-Driven KYC, KYB, AML & Biometrics
FLORIANA, Malta, Sept. 30, 2025 /PRNewswire/ -- ArriTech today announced the next…
CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML
New investors NEA and SR One lead round alongside existing investors OrbiMed,…
Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML
SAN DIEGO and TORONTO, July 15, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences…
